Related Experiment Video
Updated: Oct 6, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
To Degrade or Not to Degrade DNMT3A
Yuhong Ma1, Britta Will2,3
1Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.
Abstract:
Aberrant DNA cytosine methylation is a critical contributor to compromised tissue regeneration and malignant transformation, particularly during aging. In this issue of Cancer Discovery, Huang and colleagues define a new class of disease-associated DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) variants with decreased de novo DNA methylation activity due increased proteasomal degradation that are able to drive clonal expansion of hematopoietic stem cells.See related article by Huang et al., p. 220.
Insights
Aberrant DNA methylation, linked to aging and cancer, can be driven by new DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) variants. These variants show reduced activity due to degradation, promoting stem cell expansion.
Area of Science:
- Epigenetics and Cancer Biology
- Molecular Mechanisms of Aging
- Hematopoiesis and Stem Cell Biology
Background:
- Aberrant DNA cytosine methylation is implicated in aging, impaired tissue regeneration, and cancer development.
- DNA methyltransferases play crucial roles in establishing and maintaining methylation patterns.
- Dysregulation of DNA methyltransferases, particularly DNMT3A, is associated with various cancers.
Purpose of the Study:
- To identify and characterize novel disease-associated variants of DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A).
- To investigate the impact of these variants on de novo DNA methylation activity and protein stability.
- To determine the role of these DNMT3A variants in the clonal expansion of hematopoietic stem cells.
Main Methods:
- Variant analysis of DNMT3A in disease contexts.
- Biochemical assays to measure de novo DNA methylation activity.
- Assessment of protein stability and proteasomal degradation pathways.
- In vitro and in vivo studies using hematopoietic stem cells.
Main Results:
- A new class of DNMT3A variants was identified, associated with disease.
- These variants exhibit significantly decreased de novo DNA methylation activity.
- Increased proteasomal degradation of these variants was observed, leading to reduced protein levels.
- The identified DNMT3A variants promote the clonal expansion of hematopoietic stem cells.
Conclusions:
- Novel DNMT3A variants contribute to disease pathogenesis through impaired DNA methylation and stem cell expansion.
- Proteasomal degradation is a key mechanism regulating the activity of these disease-associated DNMT3A variants.
- Targeting DNMT3A stability or activity may offer therapeutic strategies for age-related diseases and cancers.
Related Concept Videos
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Nuclear Export of mRNA
Abnormal Proliferation
RNA Stability
MicroRNAs
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...

